← Back to Clinical Trials
Recruiting NCT06696469

NCT06696469 Feasibility and Reliability of Using BeCureTM Virtual Reality in Patients With Stroke

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06696469
Status Recruiting
Phase
Sponsor Ankara University
Condition Stroke Patients
Study Type OBSERVATIONAL
Enrollment 34 participants
Start Date 2024-06-22
Primary Completion 2026-06-22

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 80 Years
Study Type OBSERVATIONAL
Interventions
Feasibility and reliability of using BeCureTM Virtual Reality in the evaluation of upper extremity motor functions in stroke patients

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 34 participants in total. It began in 2024-06-22 with a primary completion date of 2026-06-22.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim of this study is to demonstrate the feasibility and reliability of using virtual reality-based BeCureTM in the assessment of upper extremity motor functions in stroke patients.It is necessary to define the appropriate patient profile for the evaluation of upper extremity motor functions in stroke patients with virtual reality method. We aimed to examine the effects of demographic characteristics, accompanying cognitive disorders and upper extremity motor disorders that may affect the evaluation and response to treatment on virtual reality applications. Therefore, BeCure TM virtual reality system can be feasibly used in the evaluation and rehabilitation of stroke patients.

Eligibility Criteria

Inclusion Criteria: 1. Patients diagnosed with stroke according to the World Health Organization with an age range of 18-80 years 2. Patients with subacute to chronic stroke 3. Patients who can understand commands 4. Patients with sitting balance 5. Patients with a first stroke attack 6. Patients who have never received virtual reality therapy 7. Upper extremity Brunnstrom Stage III and above 8. Patients with a spasticity level below 3 according to the Modified Ashworth Scale (MAS) in the affected upper extremity (MAS 1-5 rating system) 9. Patients who agreed to participate in the study and signed the informed consent form Exclusion Criteria: 1. History of seizures or epilepsy (except childhood febrile seizures), 2. Arthritis or pain in the affected upper limb that limits repetitive exercise, 3. Severe aphasia, cognitive impairment (premorbid dementia) or psychiatric disorders, 4. Spasticity in the affected arm is 3 or more compared to MAS, 5. Patients without sitting balance, 6. Patients with posterior cerebral artery infarction, 7. Patients with subarachnoid hemorrhage, 8. Patients with visual impairments that may affect the virtual reality application

Contact & Investigator

Central Contact

S. K. Professor

✉ sehim.kutlay@gmail.com

📞 905325625906

Principal Investigator

Sehim Kutlay, Professor

STUDY DIRECTOR

Ankara University

Frequently Asked Questions

Who can join the NCT06696469 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Stroke Patients. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06696469 currently recruiting?

Yes, NCT06696469 is actively recruiting participants. Contact the research team at sehim.kutlay@gmail.com for enrollment information.

Where is the NCT06696469 trial being conducted?

This trial is being conducted at Ankara, Turkey (Türkiye).

Who is sponsoring the NCT06696469 clinical trial?

NCT06696469 is sponsored by Ankara University. The principal investigator is Sehim Kutlay, Professor at Ankara University. The trial plans to enroll 34 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology